Compton Capital Management’s GSK GSK Stock Holding History

Compton Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,894	Closed	-$212K	–	125
2022 Q1	$212K	Hold	3,894	–	–	0.06%	154
2021 Q4	$215K	Buy	+3,894	New	+$203K	0.06%	158
2020 Q3	–	Sell	-4,694	Closed	-$239K	–	135
2020 Q2	$239K	Hold	4,694	–	–	0.1%	120
2020 Q1	$222K	Hold	4,694	–	–	0.11%	117
2019 Q4	$276K	Hold	4,694	–	–	0.11%	119
2019 Q3	$250K	Hold	4,694	–	–	0.11%	121
2019 Q2	$235K	Hold	4,694	–	–	0.1%	125
2019 Q1	$245K	Hold	4,694	–	–	0.11%	119
2018 Q4	$224K	Sell	4,694 -554	-11%	-$27.3K	0.11%	127
2018 Q3	$264K	Hold	5,248	–	–	0.1%	131
2018 Q2	$264K	Hold	5,248	–	–	0.11%	128
2018 Q1	$256K	Hold	5,248	–	–	0.11%	132
2017 Q4	$233K	Hold	5,248	–	–	0.1%	136
2017 Q3	$266K	Hold	5,248	–	–	0.12%	125
2017 Q2	$283K	Hold	5,248	–	–	0.13%	123
2017 Q1	$277K	Hold	5,248	–	–	0.14%	117
2016 Q4	$253K	Sell	5,248 -5,029	-49%	-$248K	0.13%	114
2016 Q3	$555K	Buy	10,277 +5,248	+104%	+$288K	0.15%	112
2016 Q2	$272K	Buy	5,029 +874	+21%	+$46K	0.15%	116
2016 Q1	$211K	Hold	4,155	–	–	0.12%	134
2015 Q4	$210K	Buy	+4,155	New	+$212K	0.12%	129
2015 Q3	–	Sell	-4,155	Closed	-$216K	–	135
2015 Q2	$216K	Hold	4,155	–	–	0.12%	134
2015 Q1	$240K	Hold	4,155	–	–	0.13%	128
2014 Q4	$222K	Hold	4,155	–	–	0.12%	134
2014 Q3	$239K	Hold	4,155	–	–	0.13%	128
2014 Q2	$278K	Hold	4,155	–	–	0.15%	117
2014 Q1	$278K	Hold	4,155	–	–	0.16%	112
2013 Q4	$277K	Buy	4,155 +143	+4%	+$9.27K	0.16%	116
2013 Q3	$252K	Sell	4,012 -1,360	-25%	-$87.5K	0.15%	118
2013 Q2	$336K	Buy	+5,372	New	+$341K	0.21%	103

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Compton Capital Management's GSK Position: Q2 2022 in Review

Compton Capital Management sold out of GSK (GSK) in Q2 2022, closing a stake of 3,894 shares — an estimated $212K sold.

Compton Capital Management first reported a position in GSK in Q2 2013 and held it in 30 quarters. The position peaked at $555K in Q3 2016. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Compton Capital Management reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
Compton Capital Management sold 3,894 GSK shares in Q2 2022, an estimated $212K.
Compton Capital Management first reported a position in GSK in Q2 2013 and held it in 30 quarters.
Compton Capital Management's GSK position peaked at $555K in Q3 2016.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Compton Capital Management's 13F filing for Q2 2022, filed 4 Aug 2022.